Abstract Malignant pleural mesothelioma (MPM) is an aggressive cancer with a very poor prognosis. Recently, immune checkpoint inhibition (ICI) has taken center stage in the currently ongoing revolution that is changing standard-of-care treatment for several malignancies, including MPM. As multiple arguments and accumulating lines of evidence are … [Read more...]
Semaglutide Blood Clots Side Effects: Ozempic, Rybelsus, and Wegovy
We have been receiving reports of people diagnosed with deep vein thrombosis (DVT), pulmonary embolism (PE), portal vein thrombosis (PVT), and ischemic stroke as possible semaglutide blood clots side effects. Ozempic, Rybelsus, and Wegovy are drugs with semaglutide as their active ingredient. Semaglutide Blood Clots Side Effects: DVT and Pulmonary … [Read more...]
Extended pleurectomy decortication and chemotherapy versus chemotherapy alone for pleural mesothelioma (MARS 2): a phase 3 randomised controlled trial
Background: Extended pleurectomy decortication for complete macroscopic resection for pleural mesothelioma has never been evaluated in a randomised trial. The aim of this study was to compare outcomes after extended pleurectomy decortication plus chemotherapy versus chemotherapy alone. Methods: MARS 2 was a phase 3, national, multicentre, … [Read more...]
Ozempic Side Effects Include Eye Problems With Possible Vision Loss
In July 2024 we learned from a recent medical study that Ozempic side effects include eye problems with possible vision loss. More specifically, nonarteritic anterior ischemic optic neuropathy (NAION) has been linked to semaglutide — the active ingredient in Ozempic as well as Wegovy and Rybelsus. As such, this finding about the new NAION Ozempic … [Read more...]
Syfovre’s Side Effects Keep It Off The Market In Europe (CHMP June 2024)
As we have been reporting since July 2023, Syfovre’s side effects include occlusive retinal vasculitis, a type of eye inflammation that blocks blood flow to the retina resulting in vision loss and potentially causing blindness. There have also been cases of non-occlusive retinal vasculitis and other types of eye inflammation. In late June 2024, … [Read more...]
Malignant Pleural Mesothelioma: Analysis of 70 Cases in the Last Decade
Malignant Pleural Mesothelioma (MPM) is an aggressive tumor linked to asbestos exposure, with a latency period of about 40 years before symptoms appear. Despite affecting a minority of exposed individuals, its risk escalates with prolonged exposure. Originating from mesothelial cells, [ Malignant Pleural Mesothelioma (MPM) ] affected 30,870 … [Read more...]
Predictive potential of MRI in differentiating the predominant component in biphasic pleural mesothelioma
Purpose: To assess the potential of apparent diffusion coefficient (ADC) values derived from diffusion weighted (DW) MRI preoperatively to predict the predominant histologic component among biphasic pleural mesothelioma (PM) tumors. Methods: ADC maps were generated from DW MRI scans. Histology and predominant component of [ biphasic pleural … [Read more...]
Blood Clots When Using Wegovy, Rybelsus, or Ozempic
Drug injury lawsuits that might be filed against the pharmaceutical company Novo Nordisk involving blood clots when using Wegovy, Rybelsus, or Ozempic are somewhat like the federal court Wegovy/Rybelsus/Ozempic MDL lawsuits involving gastrointestinal and stomach problems because they would involve similar — but different — liability issues, such … [Read more...]
Syfovre: Eye Problems After Injection of Syfovre (pegcetacoplan)
This blog post is about a 78-year-old woman with Syfovre eye problems involving vision loss in the first part of 2023. This Syfovre side effects case was reported in “Retinal vasculitis following intravitreal pegcetacoplan administration”, a medical journal article that appeared in the March 2024 edition of the American Journal of Ophthalmology … [Read more...]
Validation of Inflammatory Prognostic Biomarkers in Pleural Mesothelioma
Asbestos exposure is known as the main elicitor of pleural mesothelioma (PM) development. The pathology’s rarity, wide range of growth patterns, and devastating prognosis have hindered a standardized treatment to date. This study intended to determine possible prognosticators contributing to adjusting the treatment allocation. This initiated the … [Read more...]
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- 6
- …
- 22
- Next Page »